{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:50:20Z","timestamp":1793767820158,"version":"4.6.1"},"reference-count":37,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T00:00:00Z","timestamp":1112659200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Small intestine bacterial overgrowth is associated with the presence of predisposing conditions, acting through different mechanisms. Therefore, the failure to define a standardized therapy may be due to a methodological bias: to treat a condition characterized by different pathophysiological mechanisms with the same pharmacological approach. Non\u2010absorbable antibiotics could have a lower efficacy than absorbable drugs in patients with blind loops which exclude a portion of the intestine from the transit.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To evaluate the efficacy of absorbable vs. non\u2010absorbable antibiotics in this subgroup of patients.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002A group of small intestine bacterial overgrowth patients with total gastrectomy or gastrojejunostomy and blind loop underwent a therapeutic trial comparing rifaximin to metronidazole. Seven patients underwent a course of rifaximin followed by a course of metronidazole on recurrence of symptoms. To compare the effect of the drugs, another two groups of patients underwent two consecutive courses of rifaximin or metronidazole. Hydrogen breath test after glucose administration and symptom severity measurement were performed.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Both drugs reduced breath H<jats:sub>2<\/jats:sub> excretion but a much better improvement was achieved after metronidazole. Symptom improvement was higher after metronidazole.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002Metronidazole is more effective than rifaximin for the treatment of small intestine bacterial overgrowth associated with the presence of a blind loop.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02397.x","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T10:58:55Z","timestamp":1112698735000},"page":"985-992","source":"Crossref","is-referenced-by-count":55,"title":["Absorbable vs. non\u2010absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind\u2010loop syndrome"],"prefix":"10.1111","volume":"21","author":[{"given":"M.","family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Missanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(79)91337-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90693-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(81)90150-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.9.4.466"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00365521.1975.12096969","article-title":"The uptake of vitamin B12 by the sediment of jejunal contents in patients with blind loop syndrome","volume":"10","author":"Schjonsby H","year":"1975","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010722314493"},{"key":"e_1_2_6_8_2","article-title":"Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin","author":"Di Stefano M","year":"2004","journal-title":"Chemotherapy"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00751.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90173-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/0016-5085(84)90204-X","article-title":"Fasting breath hydrogen concentration: normal values and clinical application","volume":"87","author":"Perman JA","year":"1984","journal-title":"Gastroenterology"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90313-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(86)90686-4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/29.11.1980"},{"key":"e_1_2_6_15_2","first-page":"147","article-title":"Breath hydrogen (H2) response to carbohydrate malabsorption after exercise","volume":"102","author":"Payne DL","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_16_2","first-page":"798","article-title":"Modification of the breath hydrogen test increased sensitivity for the detection of carbohydrate malabsorption","volume":"100","author":"Kotler OP","year":"1982","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90475-Z"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90884-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.6.662"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196606162742402"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(61)80005-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528309181596"},{"key":"e_1_2_6_23_2","first-page":"1523","volume-title":"Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management","author":"Toskes PP","year":"1998"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90647-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/135.Supplement.S25"},{"key":"e_1_2_6_26_2","first-page":"409","article-title":"Tetracycline kinetics in undernourished subjects","volume":"19","author":"Raghuram TC","year":"1981","journal-title":"lnt J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-2-215"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.10.12.963"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0300-5089(21)00212-1","article-title":"Antimicrobial therapy of digestive disease","volume":"8","author":"Joiner KA","year":"1979","journal-title":"Clin Gastroenterol"},{"key":"e_1_2_6_30_2","first-page":"33","article-title":"Malabsorption in small intestinal diverticulosis treated with a low dosage sulphonamide\u2010trimethoprim","volume":"24","author":"Elsborg L","year":"1977","journal-title":"Dan Med Bull"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70336-7"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01016.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549030-00009"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90004-Q"},{"key":"e_1_2_6_35_2","first-page":"257","article-title":"In vitro and in vivo evaluation of L\/105, a new topical intestinal rifamycin","volume":"5","author":"Venturini AP","year":"1986","journal-title":"Chemioterapia"},{"key":"e_1_2_6_36_2","first-page":"691","article-title":"Treatment of hepatic encephalopathy with L\/105, a new non\u2010absorbable rifamycin","volume":"10","author":"Eftimiadi C","year":"1984","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00145a020"},{"key":"e_1_2_6_38_2","first-page":"365","article-title":"In vitro activity of rifaximin and rifampicin against some anaerobic bacteria","author":"Lamanna A","year":"1984","journal-title":"Chemotherapia"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02397.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02397.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:27:16Z","timestamp":1697232436000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02397.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02397.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02397.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}